Page 1

Immunic THERAPEUTICS Immunic , Inc. Reports Second Quarter 2026 Financial Results and Provides Corporate Update -Leadership Team Expanded with Key Executive Appointments , Including Chief Executive Officer , Chief Medical Officer and Chair of the Board of Directors , to Support Clinical Development , as well as NDA and Commercial Readiness - - Pivotal Phase 3 ENSURE Trials of Vidofludimus Calcium in Relapsing Multiple Sclerosis on Track , with Top - Line Data Expected by End of 2026 - - Continued Preparations for Phase 3 Trial of Vidofludimus Calcium in Progressive Multiple Sclerosis , with Initiation Planned Later This Year - NEW YORK , August 11 , 2026 - Immunic , Inc. ( Nasdaq : IMUX ) , a late - stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases , today reported financial results for the second quarter ended June 30 , 2026 , and provided a corporate update . " During the second quarter , we continued to execute across our late - stage development priorities as we advance toward what we believe will be a transformational period for Immunic , ” said Erik Lundgren , Chief Executive Officer of Immunic . " As we prepare for the next stage of Immunic's growth , we have continued to strengthen our board and team with world - class multiple sclerosis ( MS ) experts whose extensive development , medical , regulatory and commercialization expertise will be instrumental as we execute on our clinical strategy and prepare for the potential regulatory filings and commercialization of vidofludimus calcium ( IMU - 838 ) . Following the successful closing of our oversubscribed private placement financing earlier this year , we are well capitalized to execute on our key strategic priorities . We believe the milestones ahead position Immunic for a significant near - term value inflection for vidofludimus calcium in relapsing MS , while continuing to unlock the substantial long - term opportunity across the broader progressive MS patient population . " Jason Tardio , President and Chief Operating Officer of Immunic , commented , " We remain highly encouraged by the consistent and differentiated profile of vidofludimus calcium , supported by additional data from our Phase 2 CALLIPER trial in progressive MS presented at this year's CMSC Annual Meeting , including favorable safety , tolerability , patient - reported , and exploratory efficacy data . Taken together , these findings reinforce our confidence in the potential of vidofludimus calcium to offer a differentiated benefit / risk profile through its novel dual mechanism of action , combining Nurr1 activation with selective DHODH inhibition . We believe this approach has the potential to deliver meaningful efficacy while maintaining the favorable safety and tolerability profile observed to date , positioning vidofludimus calcium as a potentially important new oral treatment option for people living with MS . " " Our Phase 3 ENSURE trials of vidofludimus calcium in relapsing MS remain on track to report top - line data by the end of 2026 , " added Michael A. Panzara , M.D. , M.P.H. , Chief Medical Officer of Immunic . " With regulatory alignment and precedent surrounding the time to first relapse primary endpoint , the path to regulatory submission upon positive trial results is clear . In parallel , we are preparing to initiate our Phase 3 progressive MS trial later this year , reinforcing our commitment to evaluating the potential of vidofludimus calcium for anyone living with MS . "